Note 3 - Acquisition of Astero Bio Corporation - Consideration Transferred (Details) - Astero [Member] $ in Thousands |
Apr. 01, 2019
USD ($)
|
---|---|
Cash consideration | $ 12,521 |
Contingent consideration | 1,931 |
Working capital adjustment | (71) |
Total consideration transferred | $ 14,381 |
X | ||||||||||
- Definition Amount of working capital adjustment associated with the acquisition of business during the period. No definition available.
|
X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|